Volume 23, Number 9—September 2017
Research
Molecular Antimicrobial Resistance Surveillance for Neisseria gonorrhoeae, Northern Territory, Australia
Table 3
Summary of mosaicPBP2-PCR–positive Neisseria gonorrhoeae samples from the Northern Territory of Australia*
Patient no. | Sex | Age group, y | Aborigine | Sample source | Date of collection | NG-MAST genotype |
---|---|---|---|---|---|---|
1 |
M |
51–55 |
No |
Urine |
January 2014 |
10038 |
2 |
M |
21–25 |
No |
Urine |
March 2014 |
2212 |
3 |
F |
26–30 |
Yes |
Urine | April 2014 | 2212 |
Pharyngeal swab |
May 2014 |
2212 |
||||
4 |
M |
26–30 |
Yes |
Urine |
April 2014 |
2212 |
5 |
F |
<20 |
Yes |
Urine |
May 2014 |
2212 |
6 |
M |
21–25 |
No |
Urine |
February 2014 |
5622 |
7 |
M |
56–60 |
No |
Urine |
December 2014 |
5622 |
8 |
M |
21–25 |
No |
Anal swab |
November 2014 |
1407 |
9 | M | 21–25 | No | Anal swab | November 2014 | 1407 |
*NG-MAST, N. gonorrhoeae multiantigen sequence typing.
Page created: August 14, 2017
Page updated: August 14, 2017
Page reviewed: August 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.